Evidence map›Paper›PMID 42495391›Full record

ArticleACS omega2026

ImagiChem: Hybrid Deterministic Image-Conditioned Generation of Chemically Valid and Drug-like Molecules from Artistic Inputs.

Rocco Buccheri, Antonio Rescifina

Abstract read
In one paragraph

Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Rocco BuccheriDepartment of Drug and Health Sciences, University of Catania, Viale A. Doria 6, 95125 Catania, Italy.
Antonio RescifinaDepartment of Drug and Health Sciences, University of Catania, Viale A. Doria 6, 95125 Catania, Italy.ORCID https://orcid.org/0000-0001-5039-2151

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Generative artificial intelligence (AI) has redefined the exploration and expansion of the chemical space. However, the systematic use of visual information as a chemical prior remains virtually unexplored. Herein, we introduce ImagiChem, a deterministic image-conditioned generative framework that transforms visual patterns into chemically valid and drug-like molecules via three complementary generation modes: a library-based engine that assembles molecules from curated pharmacophore cores guided by pixel statistics, a rule-based from-scratch generator whose structural blueprint is governed by the global image profile, and a hybrid mode that combines both engines and merges their outputs. By encoding local color distributions, gradient statistics, and texture descriptors, as well as global image features, such as spatial coherence, chromatic harmony, and morphological class, into an alphabet of atomic, functional, and topological rules, ImagiChem establishes a direct multimodal mapping between visual features and molecular connectivity. This approach ensures compliance with physicochemical constraints, such as the Lipinski and Veber criteria, low pan-assay interference compounds (PAINS) incidence, and synthetic accessibility (SA), while yielding over 99% novel structures absent from current chemical databases. Statistical validation demonstrated that structured artistic inputs significantly enriched the yield of valid molecular hits compared with pooled random noise, particularly when using library-based and hybrid generation modes. ImagiChem introduces a new modality for chemical generation that conceptually bridges computer vision, molecular design, and human creativity, thereby expanding the frontier of computational chemistry into the domain of visual cognition.

Identifiers

PMID42495391
PMCPMC13393192

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.